Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?

被引：2
|
作者：
Catanese, Silvia [1 ,2 ]
Lordick, Florian [2 ]
机构：
[1] Univ Pisa, Azienda Osped Univ Pisana AOUP, Dept Med Oncol, Pisa, Italy
[2] Univ Leipzig, Univ Canc Ctr Leipzig UCCL, Med Ctr, Dept Med Oncol Gastroenterol Hepatol Pulmonol & I, Leipzig, Germany
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 24期
关键词：
2ND-LINE THERAPY; DOUBLE-BLIND; OPEN-LABEL; PHASE-III; SORAFENIB; MULTICENTER; CAMRELIZUMAB;
D O I：
10.21037/atm-20-4438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Incidence of Hyper Progressive Disease in Combination immunotherapy and anti-PD-1/PD-L1 Monotherapy for unresectable Hepatocellular Carcinoma
    Aoki, Tomoko
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Ida, Hiroshi
    Minami, Yasunori
    Tsurusaki, Masakatsu
    Nishida, Naoshi
    LIVER CANCER, 2024, 13 (01) : 56 - 69
  • [32] Genomics in hepatocellular carcinoma—a big step forward
    Ryosuke Tateishi
    Masao Omata
    Nature Reviews Gastroenterology & Hepatology, 2012, 9 : 69 - 70
  • [33] Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis
    Li, Yangyang
    Liu, Wendao
    Chen, Junwei
    Chen, Yongxin
    Guo, Jiandong
    Pang, Huajin
    Zhang, Wentao
    An, Chao
    Li, Chengzhi
    CANCER MEDICINE, 2024, 13 (01):
  • [34] Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
    Lu, Jia-Cheng
    Zhang, Peng-Fei
    Huang, Xiao-Yong
    Guo, Xiao-Jun
    Gao, Chao
    Zeng, Hai-Ying
    Zheng, Yi-Min
    Wang, Si-Wei
    Cai, Jia-Bin
    Sun, Qi-Man
    Shi, Ying-Hong
    Zhou, Jian
    Ke, Ai-Wu
    Shi, Guo-Ming
    Fan, Jia
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [35] Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).
    Zhao, Hong
    Zhou, Aiping
    Tu, Jianfei
    Bai, Yuxian
    Mao, Xianhai
    Song, Tianqiang
    Li, Bo
    Dai, Wenxiang
    Lv, Jing
    Wang, Jufeng
    Che, Xu
    Liu, Lianxin
    Zhang, Lianhai
    Wu, Wei
    Cai, Jianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [37] A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1
    He, Meiling
    Liang, Chunfeng
    Pang, Yadan
    Jiang, Mengjie
    Long, Meiying
    Yao, Zhongqiang
    Wang, Xiaoting
    Zhang, Ruijun
    Wu, Qiaoyuan
    Liang, Shixiong
    Li, Jianxu
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 913 - 925
  • [38] Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma
    Zheng, Zhiying
    Ma, Mingxi
    Han, Xiuping
    Li, Xiao
    Huang, Jinxin
    Zhao, Yuetong
    Liu, Hanyuan
    Kang, Junwei
    Kong, Xiangyi
    Sun, Guoqiang
    Sun, Guangshun
    Kong, Jie
    Tang, Weiwei
    Shao, Guoqiang
    Xiong, Fei
    Song, Jinhua
    ACTA BIOMATERIALIA, 2023, 157 : 337 - 351
  • [39] Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy
    Nahar, K. J.
    Rawson, R. V.
    Sandanayake, N.
    Tattersal, S.
    Carlino, M. S.
    Palendira, U.
    Scolyer, R. A.
    Long, G. V.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 552 - 552
  • [40] HEPATOCELLULAR CARCINOMA IN 2011 Genomics in hepatocellular carcinoma-a big step forward
    Tateishi, Ryosuke
    Omata, Masao
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (02) : 69 - 70
12345